Introduction {#Sec1}
============

Liraglutide is a once-daily human glucagon-like peptide-1 (GLP-1) analogue available for the treatment of type 2 diabetes (T2D), and its efficacy and safety have been demonstrated in the Liraglutide Effect and Action in Diabetes (LEAD) study programme \[[@CR1]--[@CR7]\]. Liraglutide has also cardioprotective benefits in patients with T2D at increased risk of cardiovascular disease \[[@CR8]\]. Liraglutide was approved in the EU in 2009, and data from real-world observational studies have further demonstrated that the benefits of liraglutide on glycated haemoglobin (HbA~1c~) and body weight loss were consistent with those obtained in the randomised LEAD trials \[[@CR9]\]. Long-term studies indicated that the benefits were sustained for up to 3 years \[[@CR10], [@CR11]\].

Liraglutide has been demonstrated to have benefits across a diverse spectrum of patients with T2D, but the extent of HbA~1c~ improvement differs within patient groups having different demographics and clinical characteristics \[[@CR12]\]. Thus, there is an unmet need to identify subgroups of patients with T2D receiving liraglutide who are most likely to have the greatest response to treatment. This information would help healthcare providers individualise treatment options and assess cost benefits. Patients and healthcare professionals could benefit from a more detailed understanding of factors associated with improved response to liraglutide.

The ReaL study (ClinicalTrials.gov identifier: NCT02255266) was the largest observational study of liraglutide in Italian clinical practice, showing that 43.5% of patients achieved HbA~1c~ reduction ≥ 1% (10.9 mmol/mol) after 12 months of treatment (primary endpoint). This manuscript reports findings from a secondary analysis performed to identify subgroups or classes of patients with T2D who were more likely to have an improved response to liraglutide owing to specific combinations of clinical and socio-demographic characteristics.

Materials and methods {#Sec2}
=====================

ReaL was an observational, retrospective, longitudinal, multicentre study involving 45 Italian diabetes clinics throughout the country. The design and methods of this real-world study have been previously reported \[[@CR13]\]. Briefly, all consecutive patients aged ≥ 18 years diagnosed with T2D and receiving their first prescription of liraglutide in 2011 were eligible for the study. This study was conducted in accordance with the Declaration of Helsinki (last amended by 59th WMA General Assembly, Seoul, October 2013) and the Guidelines for Good Pharmacoepidemiology Practices (ICH-GPP Revision 2, April, 2007). A written informed consent, approved by an independent ethics committee, was signed by all patients before data collection. Data on a range of key clinical variables were obtained from electronic medical records. Information on fasting plasma glucose (FPG), body weight, body mass index (BMI), diabetes duration, presence of diabetes complications, liraglutide treatment, and treatment with other oral antidiabetic drugs (OADs) was extracted at the date of the first liraglutide prescription at baseline in 2011 and after 12 months. The frequency of patients achieving HbA~1c~ reduction ≥ 1% (10.9 mmol/mol) after 12 months' treatment (primary endpoint) was calculated. This primary endpoint was selected because it represents a mean effect seen in randomised clinical trials of liraglutide and is a strong indicator of effectiveness that is meaningful to both patients and clinicians. It is also in line with the trend in clinical care to individualise specific HbA~1c~ targets. Information on side effects and adverse events was not explored, since it was not available in the electronic medical records in a standardised format.

Statistical analysis {#Sec3}
--------------------

Results are expressed as mean and standard deviation (SD) for continuous variables, and proportion and percentages for categorical measures, respectively. Between-group patient characteristics were compared with a Mann--Whitney *U* test or Student's *t* test (as appropriate) for continuous variables, or a Chi-square test for categorical variables. Univariate logistic regression was used to identify baseline characteristics of patients who achieved the primary endpoint (HbA~1c~ reduction ≥ 1.0% \[10.9 mmol/mol\] at 12 months), compared with those who did not.

Multivariate logistic regression analysis was performed to identify independent factors associated with the endpoint after adjustment for other variables. Covariates included in the multivariate analysis were age, sex, diabetes duration, baseline HbA~1c~, FPG, BMI, presence of diabetes complications, treatment at the first prescription of liraglutide (baseline), treatment modality, liraglutide dose, hypertension, dyslipidaemia, and estimated glomerular filtration rate (eGFR) levels. Standardised criteria which were used for diagnosis of hypertension were not established a priori for this study. Data were collected from electronic medical records, but in the Italian national guidelines, hypertension and dyslipidaemia cut-offs are blood pressure (BP) values ≥ 140/90 mmHg and low-density lipoprotein (LDL)-cholesterol ≥ 100 mg/dl, respectively. Covariates used in the multivariate analysis were chosen based on clinical judgment and did not depend on reaching statistical significance in the univariate analysis. Results are shown as odds ratios (ORs) and 95% confidence intervals (CI).

RECursive Partitioning and AMalgamation (RECPAM) analysis, a tree-based statistical method that integrates standard regression and tree-growing techniques, was used to detect potential interactions among the different variables in predicting reduction of at least 1% in HbA~1c~ and identify homogeneous and distinct subgroups of patients with increased likelihood of reaching the endpoint \[[@CR14]\]. In diabetes, RECPAM analysis has been previously used to identify: patients with T2D at risk of microalbuminuria \[[@CR15]\], factors associated with impaired quality of life in patients using continuous subcutaneous insulin infusion \[[@CR16]\], and patients at higher risk of cardiovascular disease \[[@CR17]\]. The RECPAM analysis was performed using SAS^®^ (Release 9.4 Cary, NC, USA) and a macro-routine written by F. Pellegrini and updated by M. Scardapane and G. Lucisano. At each partitioning step, the RECPAM method automatically chose the covariate and best binary split to maximise the difference in risk of experiencing the outcome. The algorithm stopped when user-defined stopping rules were met. In this case, each final class was required to have at least 100 patients in total and 30 patients with the target endpoint.

The set of variables tested in the RECPAM analysis was the same tested in the multivariate logistic regression analysis. Continuous variables were not categorised so as to allow the algorithm to choose the natural cut-off points when identifying distinct subgroups of patients. For each subgroup or class, the proportions (%) of patients reaching the endpoint and the likelihood (ORs and 95% CI) to reach the endpoint versus the reference subgroup were obtained. Finally, to detect additional global correlates (i.e. variables playing a role for all patients, irrespective of the interactions detected by RECPAM), a logistic regression model with RECPAM-identified subgroups and all the covariates ruled out by the algorithm was performed. No imputation was used for missing data, and sensitivity analyses were not performed.

Results {#Sec4}
=======

A total of 1723 patients were included in the analysis. Baseline characteristics, including diabetes complications and prior treatment regimens, are shown in Table [1](#Tab1){ref-type="table"}. At baseline, most patients were being treated with metformin, either as monotherapy (*n* = 803, 46.6%) or with sulphonylureas (*n* = 457, 26.5%). Few patients (*n* = 100, 5.8%) received insulin. Most patients received liraglutide as an add-on to previous therapies (63.2%), with 33.4% replacing another prior drug with liraglutide, and 3.4% reducing the number of prior therapies. Mean BMI at baseline was 35.6 ± 5.9 kg/m^2^, with 83.3% of patients considered to have obesity (BMI \> 30 kg/m^2^).Table 1Baseline characteristics of 1723 patients with type 2 diabetes prior to starting liraglutide treatmentVariableCategoryValueAge (years)58.9 ± 9.5Sex (%)Female45.1Diabetes duration (years)9.6 ± 7.1HbA~1c~ (% points)8.3 ± 1.4\
(67 ± 15.3 mmol/mol)Fasting plasma glucose (mg/dL)171.8 ± 52.2BMI (kg/m^2^)35.6 ± 5.9Presence of diabetes complications (%) Coronary heart diseaseNo86.9Yes13.1 StrokeNo98.1Yes1.9 Peripheral vascular diseaseNo93.3Yes6.7 Diabetic retinopathyNo81.5Yes18.5 Sensory-motor neuropathyNo86.5Yes13.5Baseline treatment (%)Metformin46.6Other monotherapy7.6Metformin + SU26.5Other dual8.6≥3 OADs3.7Insulin ± OADs7Liraglutide treatment modality (%)Switch33.4Add-on63.2Reduce3.4Systolic blood pressure (mmHg)139.3 ± 18.1Diastolic blood pressure (mmHg)81.3 ± 10.0Hypertension (≥ 140/90 mmHg) (%)No39.8Yes60.2Total cholesterol (mg/dL)180.8 ± 39.8HDL-cholesterol (mg/dL)45.0 ± 10.9LDL-cholesterol (mg/dL)102.9 ± 35.3Dyslipidaemia (%)No34.4Yes65.6eGFR (%)≤ 30 mL/min/1.73 m^2^0.1\> 30-- \< 60 mL/min/1.73 m^2^11.4≥ 60-- \< 90 mL/min/1.73 m^2^43.1≥ 90 mL/min/1.73 m^2^45.4Values are mean ± SD or %Add-on, liraglutide added to prior therapy; BMI, body mass Index; eGFR, estimated glomerular filtration rate (using the Chronic Kidney Disease-Epidemiology Collaboration formula); HbA~1c~, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; reduce, number of prior OADs was reduced with addition of liraglutide; OAD, oral antidiabetic drug; SU, sulphonylurea; switch, switch to liraglutide from prior therapy

By 12 months (primary endpoint analysis), a total of 194/1723 (11.2%) patients had discontinued liraglutide treatment. For those with a known reason (*n* = 166), most (*n* = 75/166) were owing to lack of effectiveness. An additional 35 discontinued due to liraglutide intolerance, 28 owing to gastrointestinal side effects, and 20 discontinued for other reasons. A total of 19 patients were non-adherent to therapy. At 12 months, there were 1325 (76.9%) patients with HbA~1c~ values available at both baseline and 12 months, and 577/1325 (43.5%) reached the primary endpoint (HbA~1c~ reduction ≥ 1.0% \[10.9 mmol/mol\]).

Patients who reached the endpoint had a shorter mean diabetes duration (9.1 ± 6.9 vs. 10.0 ± 7.0 years, *p *= 0.04), higher mean HbA~1c~ at baseline (9.0 ± 1.4 \[75 ± 15.3 mmol/mol\] vs. 7.7 ± 1.0% \[61 ± 10.9 mmol/mol\], *p *\< 0.0001), higher mean diastolic BP (82.6 ± 10.0 vs. 80.3 ± 9.8 mmHg, *p *= 0.0002) and higher mean total cholesterol levels (183.1 ± 41.8 vs. 177.2 ± 37.4 mg/dL, *p *= 0.02) compared to those who failed to reach the primary endpoint. Mean BMI was nearly identical in the two groups (35.6 ± 5.8 vs. 35.5 ± 5.8 kg/m^2^, *p *= 0.72), and there were no significant differences in mean high-density lipoprotein (HDL)-cholesterol (*p *= 0.11) or mean LDL-cholesterol (*p *= 0.16). There were no significant differences between the two groups in the proportion of patients using antihypertensive or lipid-lowering medications or other diabetes treatments at baseline.

Logistic regression analysis {#Sec5}
----------------------------

The odds of achieving the primary endpoint, by patient characteristic, are shown in Table [2](#Tab2){ref-type="table"}. In the univariate analysis, higher HbA~1c~ at baseline was associated with significantly higher odds (OR 2.78; 95% CI \[2.43; 3.18\]; *p *\< 0.0001). Shorter diabetes duration was associated with a significantly lower odds of reaching the endpoint (OR 0.98; 95% CI \[0.97; 1.00\]; *p *= 0.04). Higher diastolic BP (OR 1.02; 95% CI \[1.01; 1.04\]; *p *= 0.0002) and higher total cholesterol (OR 1.00; 95% CI \[1.00; 1.01\]; *p =* 0.0203) were also associated with significantly increased odds of reaching the endpoint. Other patient characteristics, such as age, sex, BMI, presence of various diabetes complications, dyslipidaemia or eGFR levels, were not significantly associated with odds of reaching the endpoint.Table 2Univariate and multivariate analysis of factors predicting reduction of HbA~1c~ ≥ 1.0% (10.9 mmol/mol) among 1325 patients^a^ after 12 months of treatment with liraglutideVariableCategoryUnivariate logistic regressionMultivariate logistic regressionOdds ratio (95% CI)*p*-valueOdds ratio (95% CI)^b^*p*-valueAgeN/A1.00 (0.99; 1.01)0.96891.02 (1.00; 1.04)0.02Diabetes duration (years, continuous)N/A0.98 (0.97; 1.00)0.040.97 (0.94; 0.99)0.007HbA~1c~ (continuous)N/A2.78 (2.43; 3.18)\< 0.00013.52 (2.90; 4.27)\< 0.0001BMI kg/m^2^ (continuous)N/A1.00 (0.98; 1.02)0.72071.01 (0.98; 1.03)0.61Baseline treatmentMetformin1.00^c^1.00^c^N/AOther monotherapy1.17 (0.76; 1.80)0.46510.91 (0.52; 1.59)0.75Metformin + SU1.01 (0.77; 1.32)0.95280.50 (0.34; 0.72)0.0002Other dual1.01 (0.67; 1.52)0.96150.59 (0.34; 1.02)0.06≥ 3 OADs1.12 (0.62; 2.02)0.70250.41 (0.19; 0.88)0.02Insulin ± OADs1.00 (0.63; 1.58)0.99630.44 (0.23; 0.85)0.02Liraglutide dose1.81.00^c^1.00^c^N/A1.21.43 (1.12; 1.82)0.00371.91 (1.40; 2.61)\< 0.0001Liraglutide treatment modalitySwitch1.00^c^1.00^c^N/AAdd-on1.74 (1.38; 2.20)\< 0.00011.86 (1.38; 2.51)\< 0.0001Reduce0.56 (0.26; 1.21)0.14180.62 (0.24; 1.59)0.32SexFemale1.00^c^Male1.09 (0.88; 1.35)0.4459Fasting plasma glucose (mg/dL, continuous)N/A1.01 (1.01; 1.02)\< 0.0001Diabetic retinopathyNo1.00^c^Yes1.17 (0.87; 1.57)0.2896Sensory-motor neuropathyNo1.00^c^Yes1.10 (0.79; 1.52)0.5731Coronary heart diseaseNo1.00^c^Yes0.85 (0.62; 1.18)0.3408StrokeNo1.00^c^Yes0.82 (0.38; 1.76)0.6052Peripheral vascular diseaseNo1.00^c^Yes0.85 (0.55; 1.32)0.4702Blood pressure (mm Hg)≤ 130/801.00^c^131--139/81--891.25 (0.77; 2.03)0.3652≥ 140/901.11 (0.86; 1.44)0.4247Systolic BP (mm Hg, continuous)N/A1.00 (1.00; 1.01)0.5617Diastolic BP (mm Hg, continuous)N/A1.02 (1.01; 1.04)0.0002HypertensionNo1.00^c^Yes0.91 (0.69; 1.19)0.4815Total cholesterol (mg/dL, continuous)N/A1.00 (1.00; 1.01)0.0203HDL-cholesterol (mg/dL, continuous)N/A1.0 (1.0; 1.0)0.1091LDL-cholesterol (mg/dL, continuous)N/A1.0 (1.0; 1.0)0.1566DyslipidaemiaNo1.00^c^Yes0.98 (0.77; 1.24)0.8573eGFR\> 901.00^c^61--900.97 (0.73; 1.29)0.847131--600.63 (0.39; 1.02)0.06030--30ncncAdd-on, liraglutide added to prior therapy; BMI, body mass index; BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; HbA~1c~, glycated haemoglobin; LDL, low-density lipoprotein; N/A, not applicable; nc, not calculated; OAD, oral antidiabetic drug; reduce, number of prior OADs was reduced with addition of liraglutide; SU, sulphonylurea; switch, switch to liraglutide from prior therapy^a^Patients who had HbA~1c~ data recorded at 12 months^b^Adjusted for age, sex, duration of diabetes, baseline HbA~1c~, FPG, BMI, presence of diabetes complications, hypertension, dyslipidaemia, eGFR levels, treatment scheme at the first prescription of liraglutide, treatment modality, and liraglutide dosage^c^Reference category

Prior treatment (including insulin) was not significantly associated with reaching the primary endpoint (*p *\> 0.05). However, after adjusting for potential confounding in the multivariate analysis, all prior treatment regimens (except for other dual therapy, *p *= 0.06) were associated with a significantly lower odds of achieving the endpoint compared with metformin monotherapy (Table [2](#Tab2){ref-type="table"}). Regarding treatment modality, patients who had liraglutide added to their prior therapy had a significantly higher odds of achieving the primary endpoint (OR 1.74 95% CI \[1.38; 2.20\]; *p *\< 0.0001) compared with patients who switched to liraglutide from their previous therapy. Those results were confirmed in the multivariate analysis.

The proportion of patients using liraglutide at higher doses increased with successive follow-up, with over a third (36.1%) using 1.8 mg at 12 months compared to 5.3% at baseline. Patients using liraglutide 1.2 mg had an increased odds (OR 1.43; 95% CI \[1.12; 1.82\]; *p *= 0.0037) of reaching the endpoint compared to those using the highest dose (1.8 mg).

RECPAM analysis {#Sec6}
---------------

The RECPAM analysis identified five distinct patient subgroups or classes with increasing odds of achieving an HbA~1c~ reduction ≥ 1.0% (10.9 mmol/mol) after 12 months (Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}). The proportion of patients reaching the endpoint ranged from 16.3% (reference group) to 83.1%. The splitting variables indicated that baseline HbA~1c~ and, to some extent, diabetes duration were the primary drivers of degree of response to liraglutide, whereas other patient-related factors were not identified as important in discriminating responder subgroups. With patients having baseline HbA~1c~ ≤ 7.5% (58 mmol/mol) considered the reference class (OR = 1.00), the odds of patients in the other classes achieving the endpoint were: Class 4: OR 2.6; 95% CI \[1.7; 4.1\], patients with HbA~1c~ between 7.5% (58 mmol/mol) and 8.2% (66 mmol/mol), diabetes duration \> 5 years; Class 3: OR 6.3; 95% CI \[3.8; 10.2\], HbA~1c~ between 7.5% (58 mmol/mol) and 8.2% (66 mmol/mol), diabetes duration \< 5 years; Class 2: OR 8.5; 95% CI \[5.5; 13.1\], HbA~1c~ between 8.2% (66 mmol/mol) and 9.1% (76 mmol/mol); and Class 1: OR 28.7; 95% CI \[17.8; 46.2\], HbA~1c~ \> 9.1%.Fig. 1Subgroups of patients with type 2 diabetes with different odds of achieving a HbA~1c~ reduction ≥ 1.0% (10.9 mmo/mol) after 12 months of treatment with liraglutide, identified using RECPAM analysis. The tree-growing algorithm modelled the odds for achieving HbA~1c~ reduction ≥ 1.0%-point using multivariate logistic regression. Splitting variables were automatically selected by the RECPAM routine among the covariates used in the multivariate analysis and are shown between branches. Cut-offs sending patients to the left or right sibling were also automatically chosen by the RECPAM routine and are reported on the relative branches.  %, proportion of patients in subgroup achieving a reduction in HbA~1c~ ≥ 1.0% (10.9 mmol/mol); circles indicate subgroups of patients and squares indicate final RECPAM classes. Numbers inside circles and squares indicate number of patients achieving HbA~1c~ reduction ≥ 1.0% (10.9 mmol/mol). HbA~1c~, glycated haemoglobin; OR, unadjusted odds ratio (95% confidence interval); RECPAM, RECursive Partitioning and AMalgamation Table 3Clinical characteristics, at baseline and after 12 months of treatment with liraglutide, by RECPAM classRECPAM classificationClass 1\
*n* = 219Class 2\
*n* = 194Class 3\
*n* = 106Class 4\
*n *= 197Class 5\
*n* = 306*p*-valueSplitting variablesHbA~1c~ \> 9.1%\
\[76 mmol/mol\]8.2% \< HbA~1c~ ≥ 9.1%\
\[66 \< HbA~1c~ ≥ 76 mmol/mol\]7.5% \< HbA1~c~ ≥ 8.2%\
\[58 \< HbA~1c~ ≥ 66 mmol/mol\]\
Diabetes duration\
≤ 5 years7.5% \< HbA~1c~ ≥ 8.2%\
\[58 \< HbA~1c~ ≥ 66 mmol/mol\]\
Diabetes duration\
\> 5 yearsHbA~1c~ ≤ 7.5%\
\[58 mmol/mol\]Unadjusted odds of HbA~1c~ being reduced by ≥ 1.0%28.7\
(17.8; 46.2)8.5\
(5.5; 13.1)6.3\
(3.8; 10.2)2.6\
(1.7; 4.1)1.00^a^Patient characteristicBaseline HbA~1c~ (%)10.2 ± 1.0\
\[88 ± 10.9 mmol/mol\]8.7 ± 0.3\
\[72 ± 3.3 mmol/mol\]7.9 ± 0.2\
\[63 ± 2.2 mmol/mol\]7.9 ± 0.2\
\[63 ± 2.2 mmol/mol\]7.0 ± 0.5\
\[53 ± 5.5 mmol/mol\]\< 0.0001Change in HbA~1c~ (%)− 2.2 ± 1.5\
\[88 ± 16.4 mmol/mol\]− 1.0 ± 1.1\
\[88 ± 12.0 mmol/mol\]− 0.9 ± 1.0\
\[88 ± 10.9 mmol/mol\]− 0.5 ± 0.9\
\[88 ± 9.8 mmol/mol\]− 0.1 ± 0.8\
\[88 ± 8.7 mmol/mol\]\< 0.0001Baseline FPG (mg/dl)223.0 ± 56.7181.5 ± 41.1157.3 ± 28.9159.7 ± 33.2137.5 ± 28.5\< 0.0001Change in FPG (mg/dl)− 59.1 ± 63.7− 28.9 ± 49.9− 20.6 ± 40.3− 14.4 ± 35.5− 7.1 ± 33.00.0002Baseline BMI (Kg/m^2^)35.6 ± 5.635.3 ± 5.637.2 ± 6.334.1 ± 5.635.7 ± 6.2\< 0.0001Change in BMI (Kg/m^2^)− 0.9 ± 2.2− 1.6 ± 2.0− 1.3 ± 1.9− 1.1 ± 1.7− 1.3 ± 2.10.02Baseline weight (Kg)101.5 ± 18.598.3 ± 17.7103.9 ± 19.193.9 ± 17.4100.2 ± 19.2\< 0.0001Change in weight (Kg)− 2.5 ± 6.1− 4.3 ± 5.3− 3.7 ± 5.2− 3.1 ± 4.7− 3.7 ± 5.80.03Age (years)57.7 ± 9.460.7 ± 8.056.0 ± 9.161.2 ± 9.359.2 ± 8.9\< 0.0001Sex (% male)57.555.248.152.356.90.46Duration diabetes (years)10.2 ± 6.911.2 ± 7.32.9 ± 1.512.1 ± 6.39.1 ± 6.8\< 0.0001Baseline treatment (%)\< 0.0001Metformin only34.73471.738.660.8Other monotherapy7.37.78.58.67.2Metformin + SU35.635.613.231.514.4Other dual therapies7.311.33.87.610.1≥ 3 OADs5.54.11.95.62.6Insulin ± OADs9.67.20.98.14.9Treatment modality (%)0.34Switch31.537.634.036.538.2Add-on67.159.865.161.457.8Reduction1.42.60.92.03.9Liraglutide dosage (%)0.00070.64.14.65.75.17.81.255.350.565.158.966.71.840.644.829.236.025.5Baseline SBP (mmHg)142.0 ± 18.4140.3 ± 16.6138.0 ± 17.9140.3 ± 18.7137.4 ± 16.80.09Change in SBP (mmHg)− 4.2 ± 18.5− 2.6 ± 16.7− 4.4 ± 16.0− 6.3 ± 19.2− 5.4 ± 17.60.57Baseline DBP (mmHg)83.5 ± 10.681.2 ± 9.481.7 ± 10.181.0 ± 9.680.0 ± 10.00.02Change in DBP (mmHg)− 1.8 ± 11.2− 0.6 ± 9.6− 1.0 ± 10.6− 2.4 ± 11.0− 1.7 ± 11.10.60Baseline total cholesterol (mg/dl)187.9 ± 43.6181.5 ± 36.3185.2 ± 38.1175.2 ± 34.9174.8 ± 38.00.007Change in total cholesterol (mg/dl)− 16.2 ± 40.1− 9.8 ± 32.3− 19.9 ± 39.6− 7.2 ± 34.7− 7.1 ± 31.00.06Baseline HDL-cholesterol (mg/dl)42.9 ± 9.545.2 ± 11.543.5 ± 10.946.5 ± 12.044.7 ± 10.40.07Change in HDL-cholesterol (mg/dl)0.6 ± 7.11.6 ± 8.31.6 ± 7.51.8 ± 8.20.9 ± 7.90.42Baseline LDL-cholesterol (mg/dl)104.2 ± 38.8104.4 ± 30.7108.5 ± 36.296.9 ± 32.1101.1 ± 32.80.13Change in LDL-cholesterol (mg/dl)− 9.4 ± 35.7− 10.8 ± 30.9− 20.4 ± 36.2− 7.3 ± 31.8− 8.7 ± 30.60.15Baseline triglycerides (mg/dl)211.6 ± 120.0169.6 ± 80.1182.9 ± 81.8163.7 ± 77.9150.8 ± 75.6\<0.0001Change in triglycerides− 35.4 ± 110.2− 7.3 ± 85.8− 16.6 ± 82.2− 11.4 ± 64.6− 0.4 ± 60.80.002Baseline albuminuria (mg/l)73.7 ± 150.339.0 ± 92.037.2 ± 55.740.6 ± 64.938.0 ± 84.10.07Change in albuminuria (mg/l)− 20.0 ± 119.20.6 ± 58.6− 1.2 ± 43.3− 15.2 ± 75.6− 13.2 ± 89.70.91Baseline eGFR (%)0.160--605.58.22.87.68.261--9062.157.268.964.555.2\> 9032.434.528.327.936.6Values are mean ± SD unless otherwise statedBMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA~1c~, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number of subjects in class; OAD, oral antidiabetic drug; RECPAM, RECursive Partitioning and AMalgamation; SBP, systolic blood pressure; SU, sulphonylurea^a^Reference category for odds ratio

Although all RECPAM classes showed HbA~1c~ reduction, the patient subgroup with the greatest odds of achieving an HbA~1c~ reduction ≥ 1.0% (10.9 mmol/mol) can be described as having the following: mean HbA~1c~ of 10.2% (88 mmol/mol), mean FPG of 223.0 mg/dL, mean diabetes duration of 10.2 years at baseline, metformin treatment ± sulphonylureas at initiation of liraglutide treatment, and liraglutide as an adjunct to prior therapy (versus discontinuation of prior treatment) (Table [3](#Tab3){ref-type="table"}). Each RECPAM class showed a reduction in mean weight, ranging from 2.5 to 4.3 kg, after 12 months' treatment with liraglutide. There was no obvious relationship between mean HbA~1c~ reduction and mean weight loss. A final logistic model adjusted with other covariates deemed clinically important and with RECPAM classes forced into the model is shown in Table [4](#Tab4){ref-type="table"}. The final logistic model with both the RECPAM classes and the covariates not entering the tree forced in the model (Table [4](#Tab4){ref-type="table"}) showed that additional global variables associated with the likelihood of reaching the endpoint were baseline treatment scheme, liraglutide dosage and treatment modality. Table 4Final logistic model^a^ showing key factors predicting reduction of HbA~1c~ ≥ 1.0% \[10.9 mmol/mol\] among 1325 patients after 12 months of treatment with liraglutide, with RECPAM classes forced in the modelFactorOR (95% CI)*p*-valueRECPAM classes Class 133.69\
(18.10--62.74)\< 0.0001 Class 210.33\
(6.23--17.12)\< 0.0001 Class 35.72\
(3.35--9.76)\< 0.0001 Class 22.89\
(1.80--4.65)\< 0.0001 Class 51.00^b^Baseline treatment Other monotherapies0.93\
(0.51--1.69)0.81 Metformin + sulphonylurea0.47\
(0.31--0.70)0.0002 Other dual therapies (metformin + TZD, metformin + glinides, SU + TZD)0.73\
(0.40--1.31)0.29 ≥ 3 OADs0.39\
(0.17--0.88)0.02 Insulin ± OADs0.47\
(0.24--0.94)0.03 Metformin only1.00^b^Liraglutide dosage (mg) 0.61.02\
(0.49--2.12)0.95 1.22.05\
(1.45--2.90)\< 0.0001 1.81.00^b^Liraglutide treatment modality Add-on to existing treatment1.79\
(1.29--2.50)0.0005 Reduction of no. of drug classes0.52\
(0.17--1.63)0.26 Switch from another drug class1.00^b^BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA~1c~, glycated haemoglobin; OAD, oral antidiabetic drug; OR, odds ratio; SU, sulphonylurea; TZD, thiazolidinedione^a^Model was adjusted for age, sex, FPG, BMI, presence of diabetes complications, hypertension, dyslipidaemia, and eGFR levels^b^Reference category

Discussion {#Sec7}
==========

This is the first RECPAM analysis to identify distinct groups of patients with T2D who were prescribed liraglutide in routine clinical practice according to their predicted degree of response to liraglutide treatment. These data can improve clinical practice by providing a deeper knowledge of factors influencing liraglutide's impact on metabolic control. The key message of this analysis is that only baseline HbA~1c~ and to a lesser extent diabetes duration were predictive of liraglutide effectiveness. Furthermore, these results for the first time clarify that HbA~1c~ reduction can exceed 2.0% when baseline levels are \> 9.0%. This finding has important clinical and health policy implications for the Italian Drugs Agency (AIFA) regulations, considering that patients with HbA~1c~ ≥ 8.5% are currently excluded from the GLP-1 receptor agonists' reimbursement policy, which requires HbA~1c~ between 7.5 (58 mmol/mol) and 8.5% (69 mmol/mol) (AIFA regulations).

Different patterns have been reported in clinical trials with regard to dose response with liraglutide. In this study, patients using the 1.2-mg liraglutide dose as maintenance dose were more likely to reach the primary endpoint than those using the higher maintenance dose (1.8 mg). This is likely due to an indication bias because patients struggling to achieve good glycaemic control were up-titrated to the higher dose, but owing to their disease severity, they still did not respond as well as healthier patients who did not require an increased dose. Escalation from the starting liraglutide dose of 0.6--1.2 mg likely occurred earlier after initiation, whereas when escalation to 1.8 mg occurred, it tended to be later in the study.

In line with existing findings \[[@CR18]--[@CR20]\], we found that the higher the baseline HbA~1c~ level, the higher the reduction achieved. Multivariate analysis showed that the likelihood of reaching the endpoint increased by 3.5 times for every 1% HbA~1c~ increase at baseline. In addition, by applying the RECPAM analysis, the study showed that the likelihood of reaching the endpoint was 28 times higher with baseline HbA~1c~ \> 9.1% as compared to baseline levels \< 7.5%. In the EVIDENCE study \[[@CR21]\], conducted in France by general practitioners and specialists, on 2029 patients, there was a mean (± SD) HbA~1c~ reduction from baseline of 1.01 ± 1.54% (from 8.46 ± 1.46 to 7.44% ± 1.20; *p *\< 0.0001); after 2 years, 29.9% (95% CI 27.7; 31.2) of patients still had HbA~1c~ ≤ 7.0%; in the cohort treated within specialist care settings (*N* = 1398), HbA~1c~ reduction was − 0.8%.

In the current study, although there were differences in the degree of liraglutide response, each RECPAM class showed decreases in HbA~1c~ from baseline after 12 months of treatment. As might be expected, a greater proportion of patients with the poorest glycaemic control at baseline achieved the primary endpoint of HbA~1c~ reduction ≥ 1.0% (10.9 mmol/mol) after 12 months, since it would be incrementally more difficult to achieve that degree of absolute HbA~1c~ reduction in patients already at or near glycaemic targets. Nevertheless, these results suggest that there is a distinct subgroup of patients for whom liraglutide treatment can help achieve HbA~1c~ reductions in excess of 2.0% (21.9 mmol/mol), a finding that may have important clinical implications.

The RECPAM algorithm selected only baseline HbA~1c~ and diabetes duration as important splitting variables when creating the responder subgroups or classes. This indicated that other patient variables were less important in determining the degree of response to liraglutide. Although BMI was not selected by the algorithm, this too may be because of the high prevalence of obesity in the sample.

Multivariate logistic regression with RECPAM categories forced into the model further confirmed that liraglutide is best used as an add-on to, rather than replacement for, prior treatment regimens (generally OADs) in T2D (OR 1.79; 95% CI \[1.29; 2.50\]). This finding is in line with current treatment guidelines \[[@CR22]\]. Interestingly, the largest patient subgroup (*n* = 306, RECPAM Class 5) (Table [3](#Tab3){ref-type="table"}) had comparatively good HbA~1c~ control (≤ 7.5% \[58 mmol/mol\]), suggesting that there is also a patient subgroup who may initiate liraglutide to pair the glycaemic control to weight loss.

Regarding the role of diabetes duration, a previous study on liraglutide reported a higher efficacy in patients with short diabetes duration \[[@CR12]\], while the ReaL study \[[@CR13]\] found improvements in metabolic control also in patients with long diabetes duration. RECPAM analysis clarifies that diabetes duration can play a role mainly for patients with HbA~1c~ levels between 7.5 and 8.2%; in particular, one in two patients with diabetes duration ≤ 5 years reached the endpoint, compared to one in three for a diabetes duration \> 5 years. The role of BMI and previous therapy as independent predictors emerging in other studies \[[@CR19], [@CR23]\] was not confirmed in our study.

A strength of this study was the large sample size. Use of real-world data also makes the findings more generalisable to patient populations seen in regular clinical practice. The observational nature of the study may introduce bias in the selection of patients who were prescribed liraglutide; however, consecutive enrolment of all patients was adopted to minimise this. Since these results reflect the clinical usage of liraglutide in Italy, they may not be generalisable to countries with different usage patterns. As a retrospective study based on electronic medical records, the completeness of information depended on the ability of participating centres to record clinical data. It should be noted that data completeness was judged satisfactory (i.e. 97.2--56.3% complete for the adjustment variables used). Insulin secretion capacity was not evaluated as a potential predictor of HbA~1c~ reduction with liraglutide, although several studies have suggested the usefulness of this parameter in predicting the effectiveness of liraglutide \[[@CR24], [@CR25]\]. This would be useful to explore in future studies. We cannot exclude the involvement of other factors, besides HbA~1c~ and partly diabetes duration, in determining HbA~1c~ reduction through liraglutide, but we analysed all factors easily available to diabetologists to guide routine clinical practice.

In conclusion, in this study, glycaemic response to liraglutide was largely driven by baseline HbA~1c~ levels and to a lesser extent by diabetes duration. The clinical benefit seems to be maximised when used as an add-on to prior therapies. All RECPAM classes showed weight loss, which appeared independent of mean HbA~1c~ reduction. RECPAM analyses suggest an urgent need to revise the AIFA criteria for reimbursement due to the finding that HbA~1c~ reduction can exceed 2.0% in people with HbA~1c~ \> 9.0%.
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